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clinically signiﬁcant chromosome abnormalities
Jean Gekas*,1,2, David-Gradus van den Berg3, Audrey Durand4,M a u dV a l l e ´e2, Hajo Izaa ¨k Johannes Wildschut3,
Emmanuel Bujold5, Jean-Claude Forest6,F r a n c ¸ois Rousseau7 and Daniel Reinharz4
In all, 80% of antenatal karyotypes are generated by Down’s syndrome screening programmes (DSSP). After a positive screening,
women are offered prenatal foetus karyotyping, the gold standard. Reliable molecular methods for rapid aneuploidy diagnosis
(RAD: ﬂuorescence in situ hybridization (FISH) and quantitative ﬂuorescence PCR (QF-PCR)) can detect common aneuploidies,
and are faster and less expensive than karyotyping. In the UK, RAD is recommended as a standalone approach in DSSP, whereas
the US guidelines recommend that RAD be followed up by karyotyping. A cost-effectiveness (CE) analysis of RAD in various
DSSP is lacking. There is a debate over the signiﬁcance of chromosome abnormalities (CA) detected with karyotyping but not
using RAD. Our objectives were to compare the CE of RAD versus karyotyping, to evaluate the clinically signiﬁcant missed CA
and to determine the impact of detecting the missed CA. We performed computer simulations to compare six screening options
followed by FISH, PCR or karyotyping using a population of 110948 pregnancies. Among the safer screening strategies, the
most cost-effective strategy was contingent screening with QF-PCR (CE ratio of $24084 per Down’s syndrome (DS) detected).
Using karyotyping, the CE ratio increased to $27898. QF-PCR missed only six clinically signiﬁcant CA of which only one was
expected to confer a high risk of an abnormal outcome. The incremental CE ratio (ICER) to ﬁnd the CA missed by RAD was
$66608 per CA. These costs are much higher than those involved for detecting DS cases. As the DSSP are mainly designed
for DS detection, it may be relevant to question the additional costs of karyotyping.
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INTRODUCTION
About 80% of antenatal cytogenetic referrals are in the context of a
screening program for DS.1 In the last 15 years, major advancements
have been made in prenatal screening for DS and prenatal diagnostic
testing (amniocentesis or chorionic villus sampling) is offered only to
pregnant women at high risk,2,3 of whom about 7% reveal a chromo-
somal abnormality (CA).4
The screening methods that identify women at high risk of having
a foetus with DS include biochemical or ultrasonography markers (or
both) combined with age-related algorithms.1 Similar to worldwide-
advised procedures,5,6 six screening options consistent with US and
Canadian guidelines are available:7,8 quadruple, combined, integrated
and serum-only integrated tests, as well as stepwise sequential (sequen-
tial) and contingent sequential (contingent) screening approaches.
After a positive prenatal screening test, women are usually offered
foetal karyotyping, which is considered as the gold standard to
conﬁrm the presence or absence of CA by counting the number of
chromosomes and looking for structural changes.1 However, the main
limitation of karyotyping remains the requirement for cell culture,
resulting in a delay of 10–14 days for test results in many clinical
genetic laboratories.9 Reliable10–13 molecular methods that are faster
(r1–3 days)14 and less expensive than karyotyping15–17 have been
developed to detect common aneuploidies, which account for 480%
of the clinically relevant CA,14 although they do not provide a full
photographic display of all chromosome pairs. Such methods include
interphase FISH and QF-PCR, collectively referred to as RAD.18
There is still no consensus on the most cost-effective strategy that
should be implemented to diagnose affected foetuses in DS screening
programs. For some authors, the implementation of RAD services
for all prenatal samples is considered to be a major step towards the
optimisation of prenatal services.17 For the UK government19 and the
UK National Screening Committee, new screening programs for DS
need not include karyotyping and can offer diagnosis with RAD as a
standalone approach.1
Nevertheless, a joint statement by the American College of Medical
Genetics and the American Society for Human Genetics20 reafﬁrmed
that all RAD test results must be followed up with karyotyping.1
Reports11,16,21,22 indicate that 15–30% of CA detected by karyotyping
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www.nature.com/ejhgwould not be detected by RAD,1 but the number of these CA with a
risk of adverse outcome above background levels are much lower,1 and
the relevance of diagnosing them via DS screening programs is
debated owing to their clinical signiﬁcance1,16–18
Actually, there is insufﬁcient data available to resolve this question.
Grimshaw et al15 noted that most investigations of these molecular
tests focused on test errors rather than on CE analysis. So far,
published reports addressing the CE of RAD versus full karyotyping
have not estimated their use in relation with the various screening
options that would comply with current guidelines for DS,15,16 and
concluded that RAD would be less cost-effective than karyotyping
owing to the cost of clinically signiﬁcant CA missed by RAD, although
the screening programs are not designed to detect them.
Given the numerous screening options to compare, any single
empirical or clinical study is unlikely to evaluate all available strategies.
Computer simulations are an elegant alternative to identify which
strategy is likely to be the most cost-effective.23,24 Using simulations,
we recently reported the impact of various ﬁrst-trimester risk cutoffs
for three different screening strategies combining ﬁrst- and second-
trimester analyses.25
In the current study, we performed simulations using data from the
Serum, Urine and Ultrasound Screening Study (SURUSS)23,26 for DS
prenatal screening and from Caine et al1 for the expected CA missed
by RAD with a potential level of adverse outcome, to: (i) compare
the CE of three approaches to diagnose CA (karyotyping, FISH or
QF-PCR) combined with six DS screening options, matched to
worldwide-advised procedures5–8 (quadruple, combined, integrated
and serum integrated tests, sequential and contingent screening
approaches) for the detection of DS through prenatal screening
programs; (ii) estimate their performance in identifying clinically
signiﬁcant CA; (iii) determine the impact of detecting missed CA by
RAD in DS screening programs by calculating the ICER if karyotyping
is performed.
METHODS
Design, data, screening options and end points
Using the modelling approach previously developed,25 we performed computer
simulations to estimate the performance of six screening options recommended
by guidelines in the US and Canada (quadruple, combined, integrated and
serum integrated tests, sequential and contingent screening approaches).7,8 We
evaluated these six screening options combined with three diagnostic
approaches (karyotyping, FISH or QF-PCR) for end points that cover the
main outcomes in DS prenatal screening.23,24 This yielded 18 potential screen-
ing algorithms. Figure 1a and b presents a simpliﬁed version of the decision
model. The end points include: (1) the global costs; (2) the false-positive rate,
which deﬁnes the number of scheduled prenatal diagnosis tests (amniocentesis
or chorionic villus sampling); (3) the number of procedure-related euploid
miscarriages; (4) the CE ratios (costs per DS detected); (5) the missed CA by
RAD and (6) the ICER to detect them by karyotyping.
The virtual population comprised 110948 pregnancies corresponding to the
number of pregnancies in 2001 in the province of Quebec.25 It allowed the
generation of a virtual population with characteristics related to the prevalence
and clinical course of non-DS or DS pregnancies, and a maternal age
distribution identical to that found in the population of Quebec, and to
simulate the costs and outcomes of all options under consideration.
To evaluate the impact of screening tests based on the gold standard of
prenatal care, only amniocentesis was used for prenatal diagnostic testing
following second-trimester screening results. However, for women who were
tested positive in the ﬁrst-trimester screening, a trans-abdominal chorionic
villous sampling (CVS) karyotyping was considered.
The screening markers and procedures used are shown in Table 1. All input
variables for simulations (screening procedures and expected CA) and their
sources are presented in Tables 2, 3 and 4.
The number of DS pregnancies shown in Table 3 represents all DS cases in
pregnancies registered for the population at each pregnancy period in 2001.
The rates of DS pregnancy losses seemed to be more important than in other
series (43%27 and 30%28), because part of these DS pregnancies are comprised
in the voluntary pregnancy terminations in the ﬁrst and second trimesters
observed in our population in 2001.25
CA missed by RAD
Because the clinical signiﬁcance (ie, preventable morbidity and mortality) of
detecting CA in perinatal and live born babies depends on the type of CA, we
used results from Caine et al1 to simulate the number and type of expected
CA in our population, to evaluate CA missed by RAD and to estimate
their potential level of adverse outcome. The study by Caine et al1constitutes
the largest published retrospective cytogenetic audit, assessing 142605
prenatal diagnoses. In the simulations, the CA were classiﬁed as detectable,
sometimes detectable or undetectable by RAD and for clinical signiﬁcance, as
background risk, low-to-high risk and high risk of adverse outcome (Table 4).
Also, we estimated the additional costs of detecting clinically signiﬁcant CA
missed by RAD by calculating the ICER24 obtained if full karyotyping is
performed.
Test performance
The distribution of SURUSS marker results in DS-affected and DS-unaffected
pregnancies was used to determine the screening test performances.23,26 All
false-positive rates and risk cutoffs were standardised to the same gestational
age (11-week gestation) for ﬁrst-trimester measurements. To compare ﬁrst-
trimester versus second-trimester screening procedures on a common basis, we
used a ﬁxed detection rate, which is more applicable than a ﬁxed false-positive
rate because applying the latter to the ﬁrst-trimester as compared with the
second-trimester results in a different detection rate, notably from the sponta-
neous losses of DS foetuses between the ﬁrst and second trimesters.29 We chose
the 90% detection rate as it is that used in the literature for test performances
and cutoffs speciﬁed for all the screening tests (integrated,26 sequential and
contingent screening tests23) used in the ﬁrst and second trimesters. Also, as of
April 2010, the UK National Screening Committee targets a detection rate of
more than 90%.6
Costs
In Canada, in accordance with the Canadian Health Care Act, all medical
necessary services are provided under the public healthcare system and are free
of charge. Costs from provincial technical units were used for laboratory and
imaging tests as previously detailed.25 Costs reported in Table 2 for screening
tests do not reﬂect the cost of any single procedure but the mean cost for all
medical necessary services provided for each screening option. Items considered
for costing included screening costs as well as healthcare and medical services
related to the following outcomes: birth, spontaneous miscarriage, elective
abortion or procedure-related euploid miscarriages. Costs are expressed in
Canadian dollars (CAD). The average exchange rate in 2007 was: 1.0748
CAD¼1.00 USD¼0.73 EUR.
CE analysis and conﬁdence intervals
All measured costs occurred within 1 year; therefore, there was no need to
discount costs and effects over time.24 Univariate sensitivity analyses25 were
performed on the rate of consent to participate in prenatal screening (65 and
80%), the rates of foetal loss from CVS (0.5, 1 and 2%) and the rates of foetal
loss from amniocentesis (1 and 1.5%). Moreover, the sensitivities and false-
positive rates of DS screening strategies varied over the ranges achieved in the
SURUSS trial.23,26 To generate 95% conﬁdence intervals (CI 95%) for global
cost estimates, a bootstrap method was used as previously described25.
RESULTS
The global cost analysis results, including the outcomes as a function
of the screening strategy and diagnostic tool that were used, are
summarised in Table 5. The CE ratio to detect DS cases (with the same
screening strategy and QF-PCR for diagnosis), the number of CA
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outcome and the ICER for detecting them by karyotyping are reported
in Table 6.
Costs and main outcomes of DS screening options
With the same DS detection rate, all screening strategies cost less
when using QF-PCR. Using the FISH test was associated with higher
Figure 1 Simpliﬁed version of the decision trees: (a) algorithms for screening options; (b) algorithms for the diagnosis procedure. Not shown in this
simpliﬁed depiction, but included in our model, is the possibility that miscarriage occurs before testing or after releasing results.
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safer screening strategies (ie, with a number of procedure-related
euploid miscarriages induced o10 per 100000 pregnancies), the most
cost-effective strategy was the contingent screening associated with
QF-PCR (global cost of $2497610 in Table 5) and CE ratio of $24084
per DS detected (Table 6). The CE ratio of this screening strategy
associated with full karyotyping would be $27898 per DS detected.
The global cost and CE ratio of the least cost-effective screening
Table 1 Deﬁnitions of screening procedures
Combined test First-trimester test based on combining nuchal translucency measurement (NT, an ultrasound measurement of the width of an area of translucency
at the back of the foetal neck early in pregnancy) with free human chorionic gonadotropin (free b-hCG), pregnancy-associated plasma protein A
(PAPP-A) and maternal age.
Quadruple test Second-trimester test based on the measurement of AFP, uE3, free b-hCG (or total hCG) and inhibin-A together with maternal age.
Integrated test The integration of measurements performed at different times of pregnancy into a single test result. Unless otherwise qualiﬁed, ‘integrated test’
refers to the integration of NTand PAPP-A in the ﬁrst trimester with the quadruple test markers in the second. The ﬁrst-trimester screening marker
results are not analyzed until the second-trimester markers are evaluated, at which point they are both assessed together.
Serum integrated test42 A variant of the integrated test without NT (using PAPP-A in the ﬁrst trimester and quadruple test markers in the second trimester).
Sequential screening23 Screening in which a ﬁrst-trimester test is performed (NT, free b-hCG and PAPP-A) and the result is interpreted immediately. If this is positive, a
diagnostic test is offered (chorionic villous sampling, CVS), but if it is not positive, second-trimester serum markers are measured (quadruple test
markers) and the ﬁrst-trimester markers are reused to form an integrated test.
Contingent screening23 Screening in which a ﬁrst-trimester test (NT, free b-hCG and PAPP-A) is used to triage the population of women screened into three groups: one
group (high-risk screen-positive) that is immediately offered a diagnostic test (CVS), a second group (screen-negative) that receives no further
screening and a third intermediate (or low-risk screen-positive) group that has second-trimester markers measured (quadruple test markers) and
the ﬁrst-trimester measurements reused to form an integrated test.
Risk cutoff The risk or likelihood of the condition being present in the foetus above which a prenatal diagnosis test is proposed.
Table 2 Analysis input variables
Cost ($) References
Input costs of screening or diagnostic tests or events
Integrated test 65 25
Sequential screening 105 25
Contingent screening 55 25
Serum integrated test 35 25
Quadruple test 25 25
Combined test 40 25
Consulting with a genetic counselor 73.90 25
CVS + diagnostic procedure karyotyping 876 25
Amniocentesis + diagnostic procedure karyotyping 500 25
CVS + diagnostic procedure QF-PCR (Aneufast) 198 25,43
Amniocentesis + diagnostic procedure
QF-PCR (Aneufast)
198 25,43
CVS + diagnostic procedure FISH 422 25,43
Amniocentesis + diagnostic procedure FISH 422 25,43
Termination of pregnancy 1357.33 25
Input variables of screening tests with
a 90% detection rate
False-positive
rate (%)
References
Integrated test (1/230 cutoff) 2.11 30,35,44
Sequential screening (1/9 cutoff, ﬁrst trimester)a 2.25 23,25
Contingent screening (1/9 cutoff, ﬁrst trimester)a 2.42 23,25
Serum integrated test (1/355 cutoff) 5.30 26,30
Quadruple test (1/545 cutoff) 10.60 26,30
Combined test (1/625 cutoff) 8.40 30,35
Different diagnostic tools Sensitivity (%) References
Karyotyping 99.40 45
QF-PCR 99.30 14
FISH 98.70 14
Abbreviations: $, Canadian dollars; CVS, chorionic villous sampling.
aSequential and contingent screening tests consist of a sequence of analysis with many possible
cutoff combinations, notably in the ﬁrst trimester23. A risk cutoff is the risk or likelihood of the
condition being present in the foetus. A woman was classiﬁed as positive if her risk estimate
was equal to or greater than the corresponding speciﬁc cutoff level. Given the published data,
for sequential and contingent screening tests, the ﬁrst-trimester high-risk cutoff we applied was
one in nine as previously advised25 and in the contingent screening approach, the lower risk
cutoff used in the ﬁrst test was 1 in 2000.23
Table 3 Demographic characteristics of the population and
assumptionsa
Population simulated Number References
Total pregnant women 110948 25
DS pregnancies at ﬁrst trimester 290 25,27,28
DS pregnancies at second trimester 190 25,27,28
DS pregnancies at third trimester 140 25,27,28
DS babies at birth 131 25,27,28
Pregnant women’s age distribution
o20 9008 25
20–24 24987 25
25–29 33421 25
30–34 27320 25
35–39 13135 25
40–44 2925 25
45Z 152 25
Events before or after screening and diagnostic
intervention
Probability
(%)
References
Consent to participate in prenatal screening 70 25
Consent for amniocentesis or CVS with
screening positive
90 25
Foetal loss from amniocentesis 0.5 25,37,46–49
Foetal loss from CVS 1.6 25,37,46–49
Proportion who terminated pregnancy with foetal DS 90 25
Abbreviations: DS, Down’s syndrome; CVS, chorionic villous sampling.
aData simulations were performed on a virtual population of 110948 pregnancies with
demographic (maternal age distribution), genetic and phenotypic (regarding DS) characteristics
of the Quebec population in the year 2001.25
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(Table 5) and $47358 per DS detected, respectively.
The difference in global cost between FISH and QF-PCR varied
from $844915 for the combined test to $220404 for the integrated
screening (Table 5). The largest difference in global cost for 100000
pregnancies between QF-PCR and karyotyping was observed with the
combined test, $2567981 ($5347554 with karyotyping and
$2779573 with QF-PCR). The highest and lowest numbers of
procedure-related euploid miscarriages occurred with the combined
test (n¼70) and the integrated test (n¼4), respectively (Table 5).
Missed CA
Clinically signiﬁcant CA were missed if the diagnosis was performed
by RAD instead of karyotyping. However, when applied to 100000
pregnancies, the contingent screening method associated with QF-PCR
missed only six clinically signiﬁcant CA (belonging to risk categories
2 or 3, ie, low-to-high and high risk), of which only one was expected
to confer a high risk of an abnormal outcome (Table 6). The
additional cost of ﬁnding these CA (ICER) by karyotyping instead
of QF-PCR was much higher than the CE ratios to ﬁnd DS cases
regardless of the screening strategy considered (Table 6). Depending
Table 4 Classiﬁcation of expected chromosome abnormalitiesa
Type of chromosome abnormalities Detectability by karyotyping b Detectability by RAD b Risk categories of clinical signiﬁcance c
Down’s syndrome T21 1 1 3
Edwards’ syndrome T18 1 1 3
Patau’s syndrome T13 1 1 3
Triploidy 11 3
Tetraploidy
Balanced structural rearrangement (inherited) 1 3 1
Robertsonian translocation (de novo or of unknown origin) 1 3 1
Marker chromosome (inherited) 1 3 1
45,X; 47,XXX; 47,XXY; 47,XYY 1 1 2
45,X mosaic; 47,XXY mosaic or sex chromosome mosaic 1 2 2
45,X structurally abnormal X or structurally abnormal X/Y chromosome 1 2 2
Balanced structural rearrangement (de novo or of unknown origin) 1 3 2
Marker chromosome (de novo or of unknown origin) 1 3 2
Other autosomal trisomy 1 3 2
Unbalanced structural rearrangement 1 3 3
Abbreviation: RAD, rapid aneuploidy diagnosis.
aClassiﬁcation according to Caine et al1 depending on their type, their detectability by karyotyping or RAD, and their clinical signiﬁcance.
bDetectability: 1¼detectable; 2¼sometimes detectable; 3¼undetectable.
cRisk categories of clinical signiﬁcance: 1¼background; 2¼low-to-high risk; 3¼high risk.
Table 5 Global costs, amount of diagnostic procedures induced and number of procedure-related euploid miscarriages
Global costsa Number of diagnostic procedures
Screening strategies QF-PCR FISH Karyotyping
Difference in karyotyping
and QF-PCRb Amniocentesis CVS
Procedure-related
euploid miscarriages
Integrated 3.06(0.0016) 3.28(0.0016) 3.36(0.0020) 0.294 908(903–913) 4(3.4–4.3)
Sequential 3.38(0.0028) 3.62(0.0033) 3.74(0.0048) 0.358 883(878–889) 102(100–103) 5(4.4–5.3)
Contingent 2.50(0.0021) 2.76(0.0029) 2.90(0.0035) 0.399 995(989–1001) 111(109–112) 6(5.3–6.9)
Serum integrated 2.14(0.0024) 2.69(0.0038) 2.88(0.0043) 0.739 2.293(2.285–2.300) 15(14–16)
Quadruple 2.08(0.0033) 3.18(0.0057) 3.55(0.0072) 1.464 4.537(4.524–4.550) 22(21–23)
Combined8.4% 2.78(0.0032) 3.62(0.0053) 5.35(0.0112) 2.568 3.760(3.746–3.772) 70(68–72)
Conﬁdence intervals are given in brackets.
aGlobal costs are expressed in MCAD (million in Canadian dollars).
bDifference of costs between karyotyping and QF-PCR are expressed in MCAD.
Table 6 CE ratios to detect DS, number of chromosome abnormalities missed by RAD, and their ICER
Number of missed CA by RAD
Screening strategies CE ratios to detect DS by QF-PCR Low-to-high (2) and high risk (3) High risk (3)
ICER to detect CA of groups
2a n d3b yk a r y o t y p i n g
Integrated 34293 5 1 59377
Sequential 33227 5 1 71646
Contingent 24084 6 1 66608
Serum integrated 24103 13 2 59034
Quadruple 23754 25 5 59077
Combined8.4% 24853 20 4 125278
Abbreviations: CE, cost-effectiveness; DS, Down’s syndrome; CA, chromosome abnormality; RAD, rapid aneuploidy diagnosis; ICER, incremental cost-effectiveness ratio.
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RAD ranged from $59034 to $125278 per CA (Table 6). Although
FISH missed the same number of clinically signiﬁcant CA as QF-PCR,
it was associated with higher costs (Table 5).
DISCUSSION
Limitations
Although our study is based on computer modelling rather than
prospective data, our results are strengthened by the use of empirical
data and true healthcare costs. It is rather unlikely that a vast
prospective clinical study comparing the 18 screening strategies
studied could realistically be performed. There is strong evidence
that computer simulations are a powerful alternative to such expensive
and hard-to-manage large-scale clinical studies.25,30
All the reported CE ratios were computed in the context of the
Quebec health care system and costs. However, with respect to cost
comparisons, relative costs (ranking of different scenarios) usually
lend themselves better to comparison. Also, given the robustness of
our ﬁndings in the sensitivity analyses, the relative performance (or
ranking) of various scenarios would likely be similar in other jurisdic-
tions. Furthermore, the demographics of the simulated population are
comparable to those found in other Western countries. Mean maternal
age and the proportion of women over 35 years are comparable to the
SURUSS26 and the First- and Second-Trimester Evaluation of Risk
trial (FASTER trial)31 populations, which are representative of women
in the UK and the USA, respectively.
RAD are the most cost-effective diagnostic tools
Our results demonstrate that RAD are the most cost-effective diag-
nostic tools and, although FISH misses the same number of clinically
signiﬁcant CA as QF-PCR, it is associated with higher costs. As DS
screening programs are mainly designed for DS detection, it may be
relevant to question the additional costs of full karyotyping to detect
other anomalies. Quality of life and anxiety measurements show a
signiﬁcantly increased health status after diagnosis with RAD,15 and
RAD allows earlier decision making in cases where the foetus has a
detected CA.32 Also, the anxiety generated after being diagnosed with
a not requested and not clinically signiﬁcant CA by karyotyping can be
prevented by using RAD.33
Furthermore, it could be more cost-effective to promote the use of
QF-PCR instead of FISH, which is generally the ﬁrst choice in genetic
laboratories, and to favour contingent screening, which this study
suggests as being the most cost-effective screening strategy for DS and
associated with a more acceptable rate of procedure-related euploid
miscarriages.
The combined test was associated with the highest number of
procedure-related euploid miscarriages, which are the main adverse
outcomes that should be reduced in DS prenatal screening.34 This is
certainly owing to the fact that CVS is associated with the highest rate
of procedure-related euploid miscarriages in women who had tested
positive in the ﬁrst trimester. Furthermore, a higher number of
unnecessary terminations could contribute to the observed excess of
procedure-related euploid miscarriages. Indeed, too early, a diagnosis
may induce an excess in unnecessary terminations of the DS cases
screened,23 as a spontaneous miscarriage may occur between the ﬁrst
and second trimesters.28 Some women who were screened as positive
in the ﬁrst trimester actually prefer to wait for an amniocentesis in the
second trimester to avoid these disadvantages of CVS. The false-
positive rate used for the combined test in our study was 8.4% for a
detection rate of 90%, as revised by the SURUSS research group.35
This agrees with the false-positive rate reported by Malone et al31 in
the FASTER trial for ﬁrst-trimester screening, as at 11 weeks, the
observed false-positive rate was 3.8% for a detection rate of 85%, and
18% for a detection rate of 95%. As other prospective trials evaluating
ﬁrst-trimester screening have reported a better efﬁciency for this
screening strategy (eg, 5% false-positive rate for a 90% detection
rate36), we simulated the CE and the number of procedure-related
euploid miscarriages using the latter values and even with these
assumptions, we conﬁrmed the costs of the combined test:
$4034243 (4024213–4044274) and 34 (33–35 for CI) for global
cost (if used with karyotyping) and for the number of procedure-
related euploid miscarriages, respectively.
RAD detect the majority of clinically signiﬁcant CA
Our ﬁndings show that only a very small number of clinically
signiﬁcant CA are missed when RAD is used as a standalone approach
and that savings can be substantial depending on the screening
strategy used. For most of the screening scenarios evaluated, the
incidence of procedure-related euploid miscarriages, which represent
foetal losses of normal babies, was higher than the number of missed
CA by RAD, especially when only high-risk CA were considered. The
choice of the screening strategy, especially when based on the false-
positive rate involved, could therefore have a more damaging impact
than the use of RAD as a standalone diagnostic approach in DS
screening programs.
ICERs to detect clinically signiﬁcant CA missed by RAD are higher
than the CE ratios to detect DS cases
We have shown that the additional costs to detect clinically signiﬁcant
CA missed by QF-PCR were much higher than the cost to detect cases
of DS, ie, between 1.7-fold with the integrated test to 5-fold higher
with the combined test. As the screening programs developed are
only designed for DS screening or other common aneuploidies
(trisomy 13 or 18) also detectable with RAD, and as women are
not always aware of the fact that other CA can be detected with
karyotyping,1,33 taking on the additional costs involved for full
karyotyping may be questionable.
Caine et al1 report that out of the 98166 amniotic ﬂuids
referred from DS screening programs, 293 substantial-risk CA would
be missed if RAD had been used. Taking a procedure-related
miscarriage rate of 0.5%,25,37 these 98166 amniocentesis tests would
have entailed 491 procedure-related miscarriages, ie, nearly twice the
number of substantial risk CA missed by RAD. Also, it remains to be
established whether withdrawal of karyotyping for pregnant women
using prenatal screening programs for DS will have a substantial effect
on the incidence of hitherto preventable morbidity and mortality in
perinatal and live born babies, as previously stated by Caine et al.1 The
incidence of birth defects are estimated at about 3.4% in the general
population38 and, in 50% of cases, medical tests show normal results
including karyotyping.39 Therefore, some recent studies support the
use of novel diagnostic approaches for these patients with DNA arrays
instead of conventional karyotyping.40 Thus, diagnostic conﬁrmatory
tools should perhaps focus on the original goal of DS prenatal
screening programs: diagnosing DS cases.
Nevertheless, pregnant women who beneﬁt from an amniocentesis
also take the risk of a procedure-related miscarriage. Therefore,
dimensions such as woman’s values that are challenged by the
additional information provided by karyotyping (including the infor-
mation brought by a normal result), by the unexpected diagnosis of
CA, and the anxiety generated by the birth of a child with clinically
signiﬁcant CA that could have been detected by karyotyping should all
be considered.41
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